Adaptive clinical trials can cut pharma costs by 30%, but uptake still slow
This article was originally published in SRA
Executive Summary
Pharmaceutical companies could cut the cost of conducting clinical trials by up to 30% by using adaptive designs instead of relying on more traditional, non-adaptive trials designed for the same purpose1.